MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
76.49
+1.01
+1.34%
After Hours: 76.49 0 0.00% 17:56 12/31 EST
OPEN
75.50
PREV CLOSE
75.48
HIGH
77.28
LOW
74.99
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
78.44
52 WEEK LOW
27.23
MARKET CAP
14.74B
P/E (TTM)
-18.2693
1D
5D
1M
3M
1Y
5Y
1D
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
Benzinga · 12/31/2025 15:01
S&P 500 Futures Decline In Premarket Trading; Cheniere Energy Ptnr, UMB Financial Lead
Dow Jones · 12/29/2025 12:31
Weekly Report: what happened at BBIO last week (1222-1226)?
Weekly Report · 12/29/2025 10:01
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2025 Update
Seeking Alpha · 12/26/2025 02:40
BridgeBio Has More Room To Run
Seeking Alpha · 12/23/2025 17:41
Abivax is the top performing biotechnology stock YTD
Seeking Alpha · 12/22/2025 21:07
BridgeBio Pharma Grants Equity Awards to New Employees Under Nasdaq Rule
Reuters · 12/22/2025 21:01
BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/22/2025 21:01
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.